These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 19000538

  • 1. Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy.
    Nakamura T, Inoue T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H, Node K.
    Clin Nephrol; 2008 Nov; 70(5):385-92. PubMed ID: 19000538
    [Abstract] [Full Text] [Related]

  • 2. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [Abstract] [Full Text] [Related]

  • 3. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
    Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K.
    Am J Med Sci; 2007 Jun; 333(6):321-6. PubMed ID: 17570983
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
    Ogawa S, Mori T, Nako K, Ito S.
    Hypertens Res; 2008 Jun; 31(6):1147-55. PubMed ID: 18716362
    [Abstract] [Full Text] [Related]

  • 5. Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.
    Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Koide H, Ueda Y, Takeuchi M, Yamagishi S.
    Clin Cardiol; 2011 Jun; 34(6):372-7. PubMed ID: 21432860
    [Abstract] [Full Text] [Related]

  • 6. Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy.
    Nakamura T, Fujiwara N, Sato E, Ueda Y, Sugaya T, Koide H.
    Kidney Blood Press Res; 2010 Jun; 33(3):213-20. PubMed ID: 20588058
    [Abstract] [Full Text] [Related]

  • 7. Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.
    Ando K, Haneda M, Ito S, Kashihara N, Node K, Nangaku M, Shimosawa T, Kishimoto J, Fujita T.
    Cardiovasc Drugs Ther; 2011 Aug; 25(4):341-7. PubMed ID: 21637969
    [Abstract] [Full Text] [Related]

  • 8. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M, Okubo S, Mizubayashi R, Isaka N, Machida H, Okamoto S, Hirota H, Takeuchi M, Kato T, Nakatani K, Mizuno O, Miyagawa K, Makino K, Okura T, Dohi Y, Ito M, Kimura G.
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [Abstract] [Full Text] [Related]

  • 9. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
    Iwai M, Chen R, Ide A, Iwanami J, Tomochika H, Tomono Y, Mogi M, Horiuchi M.
    J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
    [Abstract] [Full Text] [Related]

  • 10. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
    Katayama S, Kawamori R, Iwamoto Y, Saito I, Kuramoto K, ATTEST Study Group.
    Hypertens Res; 2008 Aug; 31(8):1499-508. PubMed ID: 18971523
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients.
    Doi M, Miyoshi T, Hirohata S, Kamikawa S, Usui S, Kaji Y, Sakane K, Ogawa H, Ninomiya Y, Kusachi S.
    Am J Med Sci; 2010 May; 339(5):433-9. PubMed ID: 20234301
    [Abstract] [Full Text] [Related]

  • 12. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy.
    Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K.
    Am J Hypertens; 2007 Nov; 20(11):1195-201. PubMed ID: 17954367
    [Abstract] [Full Text] [Related]

  • 13. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
    Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H.
    Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
    [Abstract] [Full Text] [Related]

  • 14. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
    Soeki T, Kitani M, Kusunose K, Yagi S, Taketani Y, Koshiba K, Wakatsuki T, Orino S, Kawano K, Sata M.
    Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
    [Abstract] [Full Text] [Related]

  • 15. Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.
    Nakamura T, Fujiwara N, Sugaya T, Ueda Y, Koide H.
    Metabolism; 2009 Aug; 58(8):1185-90. PubMed ID: 19481229
    [Abstract] [Full Text] [Related]

  • 16. Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.
    Abe M, Maruyama N, Suzuki H, Fujii Y, Ito M, Yoshida Y, Okada K, Soma M.
    Hypertens Res; 2012 Aug; 35(8):874-81. PubMed ID: 22592665
    [Abstract] [Full Text] [Related]

  • 17. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y, O'Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K.
    Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
    [Abstract] [Full Text] [Related]

  • 18. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.
    Uzui H, Morishita T, Nakano A, Amaya N, Fukuoka Y, Ishida K, Arakawa K, Lee JD, Tada H.
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):304-9. PubMed ID: 24288395
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, Matsuoka H.
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [Abstract] [Full Text] [Related]

  • 20. Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats.
    Fujimoto S, Satoh M, Nagasu H, Horike H, Sasaki T, Kashihara N.
    Nephrol Dial Transplant; 2009 Dec; 24(12):3651-8. PubMed ID: 19666664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.